SCHEMBL9918692

SCHEMBL9918692

Clc1nnnc2[nH]ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 3/20 0.44
AXL P30530 2/20 0.44
TTBK1 Q5TCY1 5/20 0.35
TTBK2 Q6IQ55 5/20 0.35
NUDT1 P36639 1/20 0.33
DYRK1A Q13627 3/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
JAK2 O60674 3/20 0.32
JAK3 P52333 2/20 0.32
IKBKB O14920 1/20 0.32
CHUK O15111 1/20 0.32
DAPK3 O43293 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
CSF1R P07333 1/20 0.32
RET P07949 1/20 0.32
IGF1R P08069 1/20 0.32
FGFR1 P11362 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9918753 0.74 PRKCI (0.35) PRKCIAXLTTBK1TTBK2NUDT1
SCHEMBL9918812 0.74 PRKCI (0.40) PRKCIAXLNUDT1DYRK1AADORA2A
SCHEMBL102201 0.70 TTBK1 (0.54) PRKCIAXLTTBK1TTBK2DYRK1A
SCHEMBL691603 0.70 PRKCI (0.44) PRKCIAXLTTBK1TTBK2NUDT1
SCHEMBL29700716 0.70 PRKCI (0.44) PRKCIAXLTTBK1TTBK2NUDT1
SCHEMBL23462047 0.68 DYRK1A (0.42) PRKCIAXLTTBK1TTBK2DYRK1A
SCHEMBL1504325 0.68 PRKCI (0.52) PRKCIAXLTTBK1TTBK2NUDT1
SCHEMBL30678619 0.68 PRKCI (0.52) PRKCIAXLTTBK1TTBK2NUDT1
SCHEMBL3124523 0.67 PRKCI (0.46) PRKCIAXLTTBK1TTBK2DYRK1A
SCHEMBL760829 0.67 CHUK (0.51) PRKCIAXLTTBK1TTBK2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012106448-A1 HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2012-08-09 WO disclosed
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
WO-2011031554-A2 HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors JAK2, JAK1, JAK3 PRKCI 156/4885AXL 724/4885TTBK1 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.